Transdermal patches ARE an excellent alternative for older adults with these side effects and should be strongly considered
For older patients experiencing dizziness, sedation, falls, and constipation from oral medications (particularly cholinesterase inhibitors), switching to a transdermal patch formulation significantly reduces these systemic side effects while maintaining therapeutic efficacy. 1, 2, 3, 4
Why Patches Are Underutilized Despite Clear Benefits
The limited use of transdermal formulations in clinical practice likely reflects:
- Prescriber habit and familiarity - Oral medications remain the default despite evidence supporting transdermal alternatives
- Cost and formulary restrictions - Patches may face insurance barriers or higher copays in some regions
- Limited availability - Not all medications have transdermal formulations (currently rivastigmine and donepezil patches are available for dementia treatment)
- Perceived complexity - Some clinicians may view patch application as more complicated than oral dosing
The Evidence Strongly Supports Transdermal Delivery
Gastrointestinal Side Effects Are Markedly Reduced
The transdermal route dramatically decreases nausea, vomiting, and constipation compared to oral formulations while maintaining equivalent efficacy 1, 3, 4. This occurs because:
- Continuous drug delivery avoids peak plasma concentrations that trigger GI symptoms
- First-pass hepatic metabolism is bypassed
- Steady-state blood levels reduce cholinergic adverse effects
Falls and Sedation Risk Is Lower
By eliminating the rapid absorption peaks seen with oral dosing, transdermal patches provide more stable drug levels throughout the day, reducing fluctuations that contribute to dizziness and sedation 5, 6.
Clinical Evidence From Real-World Settings
Recent case reports demonstrate that patients who developed intolerable GI symptoms with oral cholinesterase inhibitors successfully continued treatment after switching to donepezil transdermal patches 2. This allowed treatment continuation rather than discontinuation, which is critical for maintaining cognitive function.
Practical Implementation
When to switch to transdermal:
- Any patient experiencing GI symptoms (nausea, vomiting, diarrhea, constipation) on oral therapy
- Patients with recurrent falls or dizziness temporally related to medication dosing
- Those with sedation affecting daytime function
- Patients with swallowing difficulties (dysphagia)
How to manage the switch:
- Apply the first patch the day after the last oral dose
- Rotate application sites daily to minimize skin reactions
- Use lipid-based emollients if mild irritation develops 7
- Most application-site reactions are mild and manageable with proper rotation 3, 4
Common Pitfalls to Avoid
Skin reactions are overestimated as a barrier - While application-site reactions occur, they are typically mild and can be managed with:
- Daily site rotation (avoid same site for 14 days)
- Avoiding recently shaved or damaged skin
- Gentle patch removal
- Topical corticosteroids for allergic reactions if needed 7
Don't assume patches are less effective - Multiple studies confirm equivalent efficacy between transdermal and oral formulations at therapeutic doses 1, 3, 4.
Guideline Support for Route Selection
The American Geriatrics Society guidelines explicitly state: "The least-invasive method of drug administration should be used" and note that while oral routes are generally preferred for convenience, alternative delivery systems should be considered when oral administration causes problematic side effects 5. The transdermal route provides steady blood concentrations without the disadvantages of injections or the GI effects of oral medications 5.
For older adults with the specific side effects you describe—dizziness, sedation, falls, and constipation—transdermal patches represent a superior delivery method that should be utilized more frequently in clinical practice.